trending Market Intelligence /marketintelligence/en/news-insights/trending/svkimfoblmrgeqrq9ctlbq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Medicure holds off launch of heart medicine

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Medicure holds off launch of heart medicine

Medicure Inc. said it was holding off on the launch of a heart treatment called Prexxartan due to a dispute.

Medicure acquired the rights to sell the drug in the U.S. and its territories in October 2017 from Carmel Biosciences Inc., which originally developed the treatment for hypertension and heart failure, as well as for the reduction of heart-related deaths.

However, Carmel is now in a dispute with the third-party manufacturer of the product, prompting Medicure to hold off on the launch.

The Canadian pharmaceutical company intended to launch Prexxartan in the first half of 2018. The company also said it has so far made an up-front payment of $100,000 to Carmel for Prexxartan.